Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 3/20 | 0.46 |
| ▸ | CBLB | Q13191 | 13/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.41 |
| ▸ | MST1 | P26927 | 1/20 | 0.40 |
| ▸ | STK4 | Q13043 | 1/20 | 0.40 |
| ▸ | STK3 | Q13188 | 1/20 | 0.40 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.40 |
| ▸ | CCKAR | P32238 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24612057 | 1.00 | CCKBR (0.46) | CCKBRCBLBLRRK2MST1STK4 | |
| SCHEMBL20098445 | 0.91 | CBLB (0.45) | CCKBRCBLBCCKAR | |
| SCHEMBL21755226 | 0.91 | CBLB (0.45) | CCKBRCBLBCCKAR | |
| SCHEMBL20098252 | 0.90 | CCKBR (0.44) | CCKBRCBLBLRRK2CCKAR | |
| SCHEMBL20098124 | 0.90 | CCKBR (0.44) | CCKBRCBLBLRRK2CCKAR | |
| SCHEMBL21755297 | 0.89 | CCKBR (0.45) | CCKBRCBLBCCKAR | |
| SCHEMBL20098264 | 0.89 | CCKBR (0.45) | CCKBRCBLBCCKAR | |
| SCHEMBL20098192 | 0.88 | CBLB (0.48) | CCKBRCBLBCCKAR | |
| SCHEMBL20098229 | 0.88 | CBLB (0.48) | CCKBRCBLBCCKAR | |
| SCHEMBL20098085 | 0.88 | CCKBR (0.48) | CCKBRCBLBCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2020-07-16 | — | — | US | disclosed |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CCKBR 509/4885CBLB 2850/4885LRRK2 4367/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | CCKBR 3869/4885CBLB 4388/4885LRRK2 2116/4885 |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CCKBR 509/4885CBLB 2850/4885LRRK2 4367/4885 |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | CCKBR 509/4885CBLB 2850/4885LRRK2 4367/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | CCKBR 3869/4885CBLB 4388/4885LRRK2 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.